“Orodispersible tablets (ODT) can be administered to any patients having difficulty in swallowing.” – Hannan, et al. Indian J Pharm Sci. 2016; 78: 2-7
Demand for patient-friendly formulations is increasing to address the diverse needs of multiple patient populations. As demand increases, pharmaceutical companies continue to look for innovative solutions to meet a broad range of patient needs. Orodispersible tablets (ODTs) can be a good fit for pediatric patients, geriatric patients and patients with dysphagia, as well as patients with low medication adherence.
Patients with dysphagia can benefit from orodispersible tablets. These tablets disperse in the mouth, eliminating the need to swallow a solid pill and addressing a key need for patients with dysphagia. In an article in the British Journal of Clinical Pharmacology, Nunn and Williams write that, with appropriate dosing, orodispersible tablets could benefit children, who, like the elderly, often have trouble swallowing solid oral dosage forms.
For this reason, orodispersible tablets could also be a good fit for patients with low medication adherence. In addition to being easy to swallow, orodispersible tablets require no food or liquid, which can make them easier to take for patients who have complex schedules or who otherwise find it difficult to take medications at mealtimes.
Pediatric patients, geriatric patients and patients suffering from dysphagia can benefit from orodispersible tablets. Orbis Biosciences knows that all patients deserve medication that suits their needs. With Precision Particle Fabrication, Orbis can develop format-flexible medications, including orodispersible tablets, so patients can receive medications in appropriate formats.